Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T.

Br J Cancer. 2007 Apr 23;96(8):1166-9.

2.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.

N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.

3.

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne CH.

Eur J Cancer. 2012 Jul;48(10):1466-75. doi: 10.1016/j.ejca.2012.02.057.

PMID:
22446022
4.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P.

Cancer Res. 2006 Apr 15;66(8):3992-5.

5.

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.

Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.

Clin Cancer Res. 2008 Dec 1;14(23):7884-95. doi: 10.1158/1078-0432.CCR-07-5165.

6.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

7.

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.

Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissière F, Le Pessot F, Sabourin JC, Tuech JJ, Michel P, Frebourg T.

Br J Cancer. 2009 Apr 21;100(8):1330-5. doi: 10.1038/sj.bjc.6605008.

8.

Cetuximab for metastatic colorectal cancer.

Garattini S, Torri V, Floriani I.

N Engl J Med. 2009 Jul 2;361(1):96; author reply 96-7. No abstract available.

PMID:
19579281
9.

KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab.

Bando H, Yoshino T, Tsuchihara K, Ogasawara N, Fuse N, Kojima T, Tahara M, Kojima M, Kaneko K, Doi T, Ochiai A, Esumi H, Ohtsu A.

Br J Cancer. 2011 Jul 26;105(3):403-6. doi: 10.1038/bjc.2011.247.

10.

Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients.

Gao J, Wang TT, Yu JW, Li YY, Shen L.

Chin J Cancer Res. 2011 Dec;23(4):271-5. doi: 10.1007/s11670-011-0271-4.

11.

Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective.

Malapelle U, Bellevicine C, Salatiello M, de Luca C, Rispo E, Riccio P, Sparano L, De Stefano A, Carlomagno C, Maiello FM, Vita G, Nappi O, Troncone G.

J Clin Pathol. 2012 Oct;65(10):940-4.

12.

Cetuximab for metastatic colorectal cancer.

Bria E, Cuppone F, Di Maio M.

N Engl J Med. 2009 Jul 2;361(1):95-6; author reply 96-7. No abstract available.

PMID:
19579280
13.

Cetuximab for metastatic colorectal cancer.

Roila F, Garassino MC, Ballatori E.

N Engl J Med. 2009 Jul 2;361(1):95; author reply 96-7. No abstract available.

PMID:
19579279
14.

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.

Normanno N, Pinto C, Castiglione F, Bardelli A, Gambacorta M, Botti G, Nappi O, Siena S, Ciardiello F, Taddei G, Marchetti A.

PLoS One. 2011;6(12):e29146. doi: 10.1371/journal.pone.0029146.

15.

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer.

Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, Rha SY, Roh JK, Ahn JB.

Cancer Res Treat. 2016 Jan;48(1):208-15. doi: 10.4143/crt.2014.314.

16.

Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.

Estevez-Garcia P, Rivera F, Molina-Pinelo S, Benavent M, Gómez J, Limón ML, Pastor MD, Martinez-Perez J, Paz-Ares L, Carnero A, Garcia-Carbonero R.

Oncotarget. 2015 Mar 20;6(8):6151-9.

17.

Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array.

Huang MY, Liu HC, Yen LC, Chang JY, Huang JJ, Wang JY, Hsiao CP, Lin SR.

J Transl Med. 2014 May 26;12:147. doi: 10.1186/1479-5876-12-147.

18.

Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer.

Nakamoto K, Nagahara H, Maeda K, Noda E, Inoue T, Yashiro M, Nishiguchi Y, Ohira M, Hirakawa K.

Oncol Lett. 2013 Apr;5(4):1295-1300.

19.

Performance Evaluation Comparison of 3 Commercially Available PCR-based KRAS Mutation Testing Platforms.

Adams JA, Post KM, Bilbo SA, Wang X, Sen JD, Cornwell AJ, Malek AJ, Cheng L.

Diagn Mol Pathol. 2014 Feb 24. [Epub ahead of print]

PMID:
24569784
20.

KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test.

De Luca C, Vigliar E, d'Anna M, Pisapia P, Bellevicine C, Malapelle U, Troncone G.

Cytojournal. 2017 Feb 24;14:5. doi: 10.4103/1742-6413.200936. eCollection 2017 Feb 24.

PMID:
28331530

Supplemental Content

Support Center